ストックスクリーナーアプリを入手
4.44
1.11%
-0.05
前日終値:
$4.49
開ける：
$4.54
24時間の取引高:
10,279
Relative Volume:
0.12
時価総額：
$105.64M
収益：
-
当期純損益:
$-44.10M
株価収益率:
-2.0776
EPS:
-2.1371
ネットキャッシュフロー:
$-49.09M
1週間 パフォーマンス:
-6.53%
1か月 パフォーマンス:
+6.73%
6か月 パフォーマンス:
-54.60%
1年 パフォーマンス:
+77.60%
1日の値動き範囲:
$4.33
$4.54
1週間の範囲:
$4.33
$4.915
52週間の値動き範囲:
$2.14
$11.88
Kalaris Therapeutics Inc Stock (KLRS) Company Profile
名前
Kalaris Therapeutics Inc
セクター
電話
650-249-2727
住所
400 CONNELL DRIVE, BERKELEY HEIGHTS
Compare KLRS vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
KLRS
Kalaris Therapeutics Inc
|
4.44 | 105.64M | 0 | -44.10M | -49.09M | -2.1371 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Kalaris Therapeutics Inc Stock (KLRS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-16 | 開始されました | Morgan Stanley | Overweight |
| 2025-12-23 | 開始されました | Chardan Capital Markets | Buy |
| 2025-11-03 | 開始されました | Citizens JMP | Mkt Outperform |
| 2025-09-03 | 開始されました | Raymond James | Strong Buy |
| 2025-07-23 | 再開されました | Piper Sandler | Neutral |
| 2025-05-07 | 開始されました | Leerink Partners | Outperform |
| 2025-04-08 | 開始されました | William Blair | Outperform |
すべてを表示
Kalaris Therapeutics Inc (KLRS) 最新ニュース
Biotech executive Keating named to board of Berkeley Heights biopharma Kalaris - ROI-NJ
Kalaris Therapeutics appoints Laurie Keating to board - Investing.com
Kalaris Therapeutics Announces Board and Audit Committee Changes - TipRanks
Kalaris Appoints Laurie Keating to Board of Directors - The Manila Times
Press Release: Kalaris Appoints Laurie Keating to Board of Directors - Moomoo
Price to book forward of Kalaris Therapeutics, Inc. – NASDAQ:KLRS - TradingView
Kalaris Therapeutics, Inc.(NasdaqGM:KLRS) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Enterprise value to EBITDA forward of Kalaris Therapeutics, Inc. – NASDAQ:KLRS - TradingView
Kalaris Therapeutics, Inc.(NasdaqGM: KLRS) added to Russell 3000E Growth Benchmark - marketscreener.com
Kalaris Therapeutics Inc. (KLRS) Q1 2026 Earnings: EPS Surprise Beats Estimates as Pre-Revenue Biotech Advances PipelineEarnings Analysis - dars.gov.et
Kalaris Therapeutics, Inc. Actuals & Estimates (NASDAQ:KLRS) - TradingView
KLRS Forecast — Price Target — Prediction for 2027 - TradingView
Kalaris Therapeutics Inc (KLRS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Kalaris to present Phase 1a data on retinal drug at ASRS meeting - Investing.com UK
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling - Investing News Network
Kalaris Therapeutics to Present Phase 1a Data for TH103 at ASRS 2026 Annual Meeting - Quiver Quantitative
Kalaris Announces Upcoming Presentation of TH103 Phase 1a Clinical Data at American Society of Retina Specialists; Ph 1b/2 Clinical Trial Actively Enrolling - GlobeNewswire Inc.
Kalaris Therapeutics Inc (KLRS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Kalaris Therapeutics Inc (KLRS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Kalaris Therapeutics Inc (KLRS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Kalaris Therapeutics Inc (KLRS) Institutional Confidence - TradingKey
Kalaris Therapeutics Inc (KLRS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kalaris Therapeutics Inc (KLRS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Kalaris Therapeutics Inc (KLRS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Kalaris Therapeutics Inc (KLRS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Kalaris Therapeutics Climbs 7.8% as Biotech Momentum Builds (KLRS)Wave Extension - dars.gov.et
KLRS Initiates Coverage On by TD Cowen -- Rating Set to Buy - GuruFocus
TD Cowen initiates Kalaris stock coverage with buy rating - Investing.com UK
TD Cowen initiates Kalaris stock coverage with buy rating By Investing.com - Investing.com Australia
Kalaris Therapeutics initiated with a Buy at TD Cowen - TipRanks
KLRS SEC FilingsKalaris Therapeutics Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Kalaris to Present at Clinical Trials at the Summit 2026 - Investing News Network
First-in-human TH103 eye trial data to be presented at Las Vegas summit - Stock Titan
KLRS Q1 2026 Earnings: Narrower Loss Beats Estimates Amid Clinical Development ProgressEPS Revision Trend - newsline.com
KLRS Q1 2026 Earnings: EPS Beat Amid Pre-Revenue Development StageAnalyst Earnings Estimate - newsline.com
Why Is Kalaris Therapeutics Inc (KLRS) Stock Down Today? - Meyka
Kalaris Therapeutics Shareholders Back Board, Pay and Auditor - TipRanks
Kalaris Therapeutics (KLRS) director granted 9,000 stock options - Stock Titan
Kalaris Therapeutics (KLRS) director receives stock options for 9,000 shares - Stock Titan
Kalaris Therapeutics (KLRS) director receives 9,000-stock option grant - Stock Titan
[Form 4] Kalaris Therapeutics, Inc. Insider Trading Activity - Stock Titan
Kalaris Therapeutics (KLRS) director awarded 9,000 stock options - Stock Titan
Kalaris Therapeutics (KLRS) director receives stock options on 9,000 shares - Stock Titan
Kalaris Therapeutics (KLRS) holders elect board, choose annual say-on-pay - Stock Titan
Kaskela Law LLC Announces Investigation on Behalf of Kalaris Therapeutics, Inc. Shareholders and Encourages Investors With Losses to Contact The FirmKLRS - ACCESS Newswire
Kalaris Therapeutics (KLRS) Slides 6.33% as Selling Pressure Mounts; Key Support in FocusMFI Overbought - newsline.com
Wedbush Maintains Kalaris Therapeutics(KLRS.US) With Buy Rating, Maintains Target Price $17 - Moomoo
Number of shareholders of Kalaris Therapeutics, Inc. – NASDAQ:KLRS - TradingView
KLRS Q1 2026 Earnings: Better-than-Expected Loss but Stock DeclinesReturn On Equity - dars.gov.et
KLRSKalaris Therapeutics Inc Stock Price and Quote - Finviz
Kalaris Therapeutics (KLRS) Surges 7.72% as Shares Approach Key ResistanceOvernight Profile - newsline.com
Kalaris Therapeutics Inc (KLRS) 財務データ
収益
当期純利益
現金流量
EPS
2.64%
大文字化:
|
ボリューム (24 時間):